Global Foot and Mouth Disease Vaccines Market 2017-2021 - Product Image

Global Foot and Mouth Disease Vaccines Market 2017-2021

  • ID: 4143925
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Biogénesis Bagó
  • Boehringer Ingelheim
  • Brilliant Bio Pharma
  • Ceva
  • Indian Imumunologicals
  • MORE
About Foot and Mouth Disease Vaccine

FMD is a severe and contagious viral disease found in cloven-hoofed animals. FMD virus leads to illness in cows, sheep, pigs, goats, deer, and other animals with divided hooves. Animals with FMD will have fever and blisters on the tongue, lips, mammary glands, in and around the mouth, and around the hooves. These blisters pop and turn into red areas called erosions. These blisters cause pain and discomfort and will lead to other symptoms such as depression, excessive salivation, anorexia, lameness, and resistance to moving or stand. The disease weakens the animals and will affect the production of meat and milk.

The analysts forecast the global foot and mouth disease vaccine market to grow at a CAGR of 8.61% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global foot and mouth disease vaccine market for 2017-2021. To calculate the market size, the report considers the revenue generated through applications such as cattle, pigs, sheep, goats, and others.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Foot and Mouth Disease Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Merck
- Brilliant Bio Pharma
- Indian Imumunologicals
- Biogénesis Bagó
- Boehringer Ingelheim

Other prominent vendors
- Bayer HealthCare
- Ceva
- Inovio Pharmaceuticals
- Plumbline Life Sciences
- SEPPIC

Market drivers
- Frequent foot-and-mouth disease (FMD) outbreaks in Asia and the Middle East.
- For a full, detailed list, view the full report

Market challenges
- Stringent government regulations coupled with adverse side effects.
- For a full, detailed list, view the full report

Market trends
- Increasing preventive measures in FMD-free areas.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the Key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Biogénesis Bagó
  • Boehringer Ingelheim
  • Brilliant Bio Pharma
  • Ceva
  • Indian Imumunologicals
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Key market highlights
PART 05: An overview of FMD

PART 06: Market landscape
  • Market overview
  • Five forces analysis
PART 07: Market segmentation by product type
  • Conventional vaccines
  • Emergency vaccines
PART 08: Market segmentation by application
  • Cattle
  • Pigs
  • Sheep and goats
  • Others
PART 09: Geographical segmentation
  • FMD vaccines market in APAC
  • FMD vaccines market in EMEA
  • FMD vaccines market in Americas
PART 10: Decision framework
  • PART 11: Drivers and challenges
  • Market drivers
  • Impact of drivers on key customer segments
  • Market challenges
  • Impact of challenges on key customer segments
PART 12: Market trends
  • Increase in inorganic growth strategies
  • Advancements in technology
  • Increasing preventive measures in FMD-free areas
PART 13: Vendor landscape
  • Competitive scenario
PART 14: Key vendor analysis
  • Biogénesis Bagó
  • Boehringer Ingelheim
  • Brilliant Bio Pharma
  • Indian Immunologicals
  • Merck
  • Other prominent vendors
PART 15: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Global FMD vaccines market snapshot
Exhibit 02: Global FMD vaccines market 2016-2021 ($ millions)
Exhibit 03: Opportunity analysis in global FMD vaccines market
Exhibit 04: Five forces analysis
Exhibit 05: Global FMD vaccines market segmentation by vaccine type 2016
Exhibit 06: Global conventional FMD vaccines market 2016-2021 ($ millions)
Exhibit 07: Global emergency FMD vaccines market 2016-2021 ($ millions)
Exhibit 08: Global FMD vaccines market segmentation by application 2016
Exhibit 09: Segmentation of global FMD vaccines market based on geography 2016 and 2021
Exhibit 10: FMD vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 11: Key countries with FMD occurrence
Exhibit 12: Market scenario in APAC
Exhibit 13: FMD vaccines market in APAC 2016-2021 ($ millions)
Exhibit 14: Key FMD outbreaks in Asian countries
Exhibit 15: Market scenario in EMEA
Exhibit 16: FMD vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: FMD vaccines market in Americas 2016-2021 ($ millions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of challenges
Exhibit 21: Competitive structure analysis of global FMD vaccines market 2016
Exhibit 22: Competitive analysis of global FMD vaccines market
Exhibit 23: Strategic success factors of companies in global FMD vaccines market
Exhibit 24: Biogénesis Bagó: Key highlights
Exhibit 25: Biogénesis Bagó: Strength assessment
Exhibit 26: Biogénesis Bagó: Strategy assessment
Exhibit 27: Biogénesis Bagó: Opportunity assessment
Exhibit 28: Boehringer Ingelheim: Key highlights
Exhibit 29: Boehringer Ingelheim: Strength assessment
Exhibit 30: Boehringer Ingelheim: Strategy assessment
Exhibit 31: Boehringer Ingelheim: Opportunity assessment
Exhibit 32: Brilliant Bio Pharma: Strength assessment
Exhibit 33: Brilliant Bio Pharma: Strategy assessment
Exhibit 34: Brilliant Bio Pharma: Opportunity assessment
Exhibit 35: Indian Immunologicals: Key highlights
Exhibit 36: Indian Immunologicals: Strength assessment
Exhibit 37: Indian Immunologicals: Strategy assessment
Exhibit 38: Indian Immunologicals: Opportunity assessment
Exhibit 39: Merck: Key highlights
Exhibit 40: Merck: Strength assessment
Exhibit 41: Merck: Strategy assessment
Exhibit 42: Merck: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bayer HealthCare
  • Biogénesis Bagó
  • Boehringer Ingelheim
  • Brilliant Bio Pharma
  • Ceva
  • Indian Imumunologicals
  • MORE
New Report Released: – Global Foot and Mouth Disease Vaccine Market 2017-2021

The author of the report recognizes the following companies as the key players in the global foot and mouth disease vaccine market: Merck, Brilliant Bio Pharma, Indian Imumunologicals, Biogénesis Bagó, and Boehringer Ingelheim.

Other Prominent Vendors in the market are: Bayer HealthCare, Ceva, Inovio Pharmaceuticals, Plumbline Life Sciences, and SEPPIC.

Commenting on the report, an analyst from the research team said: “One trend in market is increase in inorganic growth strategies. The market has been witnessing a trend of increased mergers and acquisitions, which will likely drive the market growth. Vendors are increasingly focusing on inorganic growth strategies to expand their presence and expertise in the market. In addition, such strategies will boost their growth and profitability in the market. These strategies will be beneficial for the new companies that aim to penetrate into the market quickly. For instance, in November 2016, Ceva announced the purchase of Hertape and Inova Biotecnologia. These are among the leading animal health companies in the world. The acquisition will enable Ceva to expand its portfolio of animal health products including FMD vaccine from Inova Biotecnologia. Also, in January 2017, Boehringer Ingelheim closed the deal to acquire Sanofi's animal health business Merial, which is one of the leading producers of FMD vaccine. The acquisition of Merial allows Boehringer Ingelheim to become the second-largest animal health company worldwide.”

According to the report, one driver in market is increase in government initiatives. The increase in government initiatives is expected to propel the market growth. Government across various FMD endemic countries has been continuously pursuing plans to eradicate FMD by conducting various programs. It is also providing funds to foster R&D activities in the market. For instance, in July 2015, Department of Animal Husbandry, Dairying & Fisheries, Government of India approved the implementation of Livestock Health and Disease Control (a centrally sponsored scheme) for the year 2015-2016. The scheme was the part of Union Budget 2015-2016 and considered the funding pattern to 50:50 between Centre and State. For the Foot and Mouth Disease Control Program, the government allocated $22.7 million fund. This program will be implemented in 351 districts in India. Funds under this program will be provided for procurement of FMD vaccines for various purposes including meeting vaccination cost, animal identification cards, and other logistical support. Also, in February 2016, the EU funded Zimbabwean government with $8.5 million aid for anthrax and FMD control. This fund will cover over a four-year period. In addition, in 2016, the FAO funded Technical Co-operation Project, which was valued at $850,000 to support FMD control in Zimbabwe. Such initiatives by the government as well as other agencies will help boost the R&D activities, thereby driving the growth in the market.

Further, the report states that one challenge in market is increase in vaccine failures. There have been reports of vaccine failures regarding safety and efficacy in the prevention and treatment of FMD. This is expected to hinder the growth prospects, particularly in developing world. The alleged vaccine failures may also pose a threat to animals in Europe and North America. FMD virus can travel with infected livestock, which is believed to have been vaccinated but without any symptoms. FMD vaccine testing report (a research study of Indian Council of Agricultural Research) stated that vaccine samples taken from Indian Immunologicals, Intervet India, and Brilliant BioPharma had no desired emulsion stability and failed in sterility tests to meet standards and ethics of vaccine production. It also stated that there is a significant drawback with the testing laboratory’s procedures. This indicates that the recent FMD outbreaks in India were due to the poor quality of vaccines. This has further resulted in huge economic losses for farmers and livestock owners as a result of mortality of their animals and production losses in lactating animals. In addition, the companies such as Intervet is using enrofloxacin instead of thimerosal for preservation. However, enrofloxacin is an antibiotic licensed only for therapeutic use, and therapeutic use of this drug is not recommended in animals and food-producing animals. Such issues would hamper the market growth.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Merck
  • Brilliant Bio Pharma
  • Indian Imumunologicals
  • Biogénesis Bagó
  • Boehringer Ingelheim
  • Bayer HealthCare
  • Ceva
  • Inovio Pharmaceuticals
  • Plumbline Life Sciences
  • SEPPIC
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll